US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
UA67760C2
(uk)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
US6518280B2
(en)
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
BR0007435A
(pt)
|
1999-01-08 |
2001-12-04 |
3M Innovative Properties Co |
Formulações e métodos para tratamento decondições associadas com mucosa com ummodificador de resposta imunológica
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6541485B1
(en)
*
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
SI1198233T1
(sl)
*
|
1999-06-10 |
2007-02-28 |
3M Innovative Properties Co |
S sulfonamidom in sulfamidom substituirani imidazokinolini
|
US6451810B1
(en)
*
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
EP1438958A1
(en)
*
|
1999-06-10 |
2004-07-21 |
3M Innovative Properties Company |
Carbamate substituted imidazoquinolines
|
US6376669B1
(en)
*
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
US20040209877A1
(en)
*
|
2000-04-13 |
2004-10-21 |
Shelby Nancy J. |
Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
|
AU2002232498B2
(en)
*
|
2000-12-08 |
2006-05-04 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6664265B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6545016B1
(en)
*
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
CA2598144A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6664260B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
UA74852C2
(en)
*
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
JP2005501550A
(ja)
*
|
2001-08-30 |
2005-01-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
|
EP1455700A4
(en)
*
|
2001-11-16 |
2007-02-14 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
*
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
WO2003072026A2
(en)
*
|
2002-02-22 |
2003-09-04 |
3M Innovative Properties Company |
Method of reducing and treating uvb-induced immunosuppression
|
EP1513524A4
(en)
*
|
2002-06-07 |
2008-09-03 |
3M Innovative Properties Co |
WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
|
DK1545597T3
(da)
|
2002-08-15 |
2011-01-31 |
3M Innovative Properties Co |
Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
|
JP2006503068A
(ja)
*
|
2002-09-26 |
2006-01-26 |
スリーエム イノベイティブ プロパティズ カンパニー |
1h−イミダゾダイマー
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
AU2003301052A1
(en)
|
2002-12-20 |
2004-07-22 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
AU2003300184B8
(en)
|
2002-12-30 |
2009-12-03 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
JP2006519020A
(ja)
*
|
2003-02-27 |
2006-08-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Tlr介在生物活性の選択的調節
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
KR20050107497A
(ko)
*
|
2003-03-07 |
2005-11-11 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
1-아미노 1h-이미다조퀴놀린
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
EP1603476A4
(en)
|
2003-03-13 |
2010-01-13 |
3M Innovative Properties Co |
PROCESS FOR REMOVING TATTOO
|
WO2004080293A2
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
KR20050109562A
(ko)
*
|
2003-03-13 |
2005-11-21 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피부의 질을 개선시키는 방법
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
US7923560B2
(en)
*
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
US20040214851A1
(en)
*
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
US7176214B2
(en)
|
2003-05-21 |
2007-02-13 |
Bristol-Myers Squibb Company |
Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
|
US20050032829A1
(en)
*
|
2003-06-06 |
2005-02-10 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
US6943255B2
(en)
*
|
2003-06-06 |
2005-09-13 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
MXPA06001004A
(es)
*
|
2003-07-31 |
2006-04-27 |
3M Innovative Properties Co |
Composiciones para encapsulacion y liberacion controlada.
|
WO2005016275A2
(en)
*
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
MXPA06001674A
(es)
*
|
2003-08-12 |
2006-05-12 |
3M Innovative Properties Co |
Compuestos que contienen imidazo hidroxilamina-sustituidos.
|
JP4913593B2
(ja)
*
|
2003-08-14 |
2012-04-11 |
スリーエム イノベイティブ プロパティズ カンパニー |
脂質修飾された免疫応答調整剤
|
AU2004266657B2
(en)
|
2003-08-14 |
2009-07-02 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
EP1660122A4
(en)
*
|
2003-08-25 |
2007-10-24 |
3M Innovative Properties Co |
IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
|
JP2007503268A
(ja)
*
|
2003-08-25 |
2007-02-22 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾化合物の送達
|
EP1658076B1
(en)
*
|
2003-08-27 |
2013-03-06 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
JP2007504172A
(ja)
*
|
2003-09-02 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
粘膜に関連した症状の処置に関する方法
|
EP1660026A4
(en)
|
2003-09-05 |
2008-07-16 |
3M Innovative Properties Co |
TREATMENT FOR CD5 + B CELL LYMPHOMA
|
WO2005033049A2
(en)
*
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
|
AU2004278014B2
(en)
|
2003-10-03 |
2011-04-28 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
CA2540598C
(en)
|
2003-10-03 |
2013-09-24 |
3M Innovative Properties Company |
Pyrazolopyridines and analogs thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
AU2004285575A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
EP1685129A4
(en)
|
2003-11-14 |
2008-10-22 |
3M Innovative Properties Co |
OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
|
CN1906192A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
羟胺取代的咪唑环化合物
|
AR046781A1
(es)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
Derivados de imidazoquinolinas. composiciones farmaceuticas.
|
CA2547085A1
(en)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
CN1914203A
(zh)
*
|
2003-12-04 |
2007-02-14 |
3M创新有限公司 |
砜取代的咪唑环醚
|
WO2005066172A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
WO2005066170A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
CA2551399A1
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
US20050239735A1
(en)
*
|
2003-12-30 |
2005-10-27 |
3M Innovative Properties Company |
Enhancement of immune responses
|
CA2559607C
(en)
*
|
2004-03-15 |
2013-02-19 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US20070166384A1
(en)
*
|
2004-04-09 |
2007-07-19 |
Zarraga Isidro Angelo E |
Methods , composition and preparations for delivery of immune response modifiers
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
WO2006038923A2
(en)
*
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US7884207B2
(en)
*
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20070259881A1
(en)
*
|
2004-06-18 |
2007-11-08 |
Dellaria Joseph F Jr |
Substituted Imidazo Ring Systems and Methods
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
PL1789042T3
(pl)
*
|
2004-09-02 |
2012-09-28 |
3M Innovative Properties Co |
Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
WO2006029223A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
US7557211B2
(en)
*
|
2004-11-12 |
2009-07-07 |
Bristol-Myers Squibb Company |
8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
|
ATE538124T1
(de)
|
2004-11-12 |
2012-01-15 |
Bristol Myers Squibb Co |
Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
JP2008526751A
(ja)
*
|
2004-12-30 |
2008-07-24 |
武田薬品工業株式会社 |
1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンエタンスルホナート及び1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンメタンスルホナート
|
EP1831221B1
(en)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
JP2008526765A
(ja)
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
EA200701584A1
(ru)
*
|
2005-01-27 |
2008-02-28 |
Альма Матер Студиорум - Университа' Ди Болонья |
Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
|
JP2008530022A
(ja)
|
2005-02-04 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫反応調節物質を含む水性ゲル処方物
|
CA2597324C
(en)
|
2005-02-09 |
2015-06-30 |
Coley Pharmaceutical Group, Inc. |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
EP1877056A2
(en)
|
2005-02-09 |
2008-01-16 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
|
AU2006213746A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
|
CA2597446A1
(en)
*
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
WO2006091567A2
(en)
*
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
EP1851220A2
(en)
*
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
US8178677B2
(en)
*
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
WO2006091647A2
(en)
*
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
JP2008533148A
(ja)
*
|
2005-03-14 |
2008-08-21 |
スリーエム イノベイティブ プロパティズ カンパニー |
光線性角化症の治療方法
|
AU2006244635A1
(en)
*
|
2005-04-01 |
2006-11-16 |
Coley Pharmaceutical Group, Inc. |
Ring closing and related methods and intermediates
|
JP2008535832A
(ja)
|
2005-04-01 |
2008-09-04 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ピラゾロピリジン−1,4−ジアミン、およびそのアナログ
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
AU2006241166A1
(en)
*
|
2005-04-25 |
2006-11-02 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
US20080234318A1
(en)
*
|
2005-08-31 |
2008-09-25 |
Kristjan Gudmundsson |
Chemical Compounds
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
JP2009507856A
(ja)
*
|
2005-09-09 |
2009-02-26 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
N−{2−[4−アミノ−2−(エトキシメチル)−1H−イミダゾ[4,5−c]キノリン−1−イル]−1,1−ジメチルエチル}メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
AU2006311871B2
(en)
|
2005-11-04 |
2011-03-03 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
|
WO2007079086A1
(en)
*
|
2005-12-28 |
2007-07-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazoloalkyl substituted imidazo ring compounds and methods
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
WO2007106854A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
|
US8088788B2
(en)
|
2006-03-15 |
2012-01-03 |
3M Innovative Properties Company |
Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
WO2007143526A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Coley Pharmaceutical Group, Inc. |
Substituted tetrahydroimidazonaphthyridines and methods
|
WO2008008432A2
(en)
*
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
US20100092401A1
(en)
*
|
2006-07-18 |
2010-04-15 |
Graceway Pharmaceuticals, Llc |
Immune response modifier formulations
|
WO2008016475A2
(en)
*
|
2006-07-31 |
2008-02-07 |
3M Innovative Properties Company |
Immune response modifier compositions and methods
|
WO2008030511A2
(en)
*
|
2006-09-06 |
2008-03-13 |
Coley Pharmaceuticial Group, Inc. |
Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
WO2008079805A1
(en)
*
|
2006-12-22 |
2008-07-03 |
3M Innovative Properties Company |
Controlled release composition and process
|
WO2008098232A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Graceway Pharmaceuticals, Llc |
Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
|
US20100160368A1
(en)
|
2008-08-18 |
2010-06-24 |
Gregory Jefferson J |
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
|
AU2009335943A1
(en)
*
|
2008-12-19 |
2013-10-24 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
|
MX2011010050A
(es)
|
2009-03-25 |
2011-12-14 |
Univ Texas |
Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
|
CA2756807A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
|
US8511006B2
(en)
*
|
2009-07-02 |
2013-08-20 |
Owens Corning Intellectual Capital, Llc |
Building-integrated solar-panel roof element systems
|
AU2010274097B2
(en)
|
2009-07-13 |
2016-06-16 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
RU2012132278A
(ru)
*
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
EA201291442A1
(ru)
|
2010-06-25 |
2013-04-30 |
Медисиз Фармасьютикал Корпорейшн |
Комбинированная терапия с криохирургией и имиквимодом с низкой дозировкой для лечения актинического кератоза
|
CN105294684B
(zh)
|
2010-08-17 |
2018-04-06 |
3M创新有限公司 |
脂质化免疫反应调节剂化合物的组合物、制剂及方法
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
EP3153180A1
(en)
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
US9492682B2
(en)
|
2011-09-14 |
2016-11-15 |
Medicis Pharmaceutical Corporation |
Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
|
ES2727481T3
(es)
|
2011-11-30 |
2019-10-16 |
Sarepta Therapeutics Inc |
Inclusión inducida de exón en atrofia muscular espinal
|
WO2013162828A1
(en)
|
2012-04-27 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
WO2014107663A2
(en)
|
2013-01-07 |
2014-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cutaneous t cell lymphoma
|
US9919029B2
(en)
|
2013-07-26 |
2018-03-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
US11020486B2
(en)
|
2013-11-05 |
2021-06-01 |
3M Innovative Properties Company |
Sesame oil based injection formulations
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
EP3166976B1
(en)
|
2014-07-09 |
2022-02-23 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
ES2952603T3
(es)
|
2015-05-20 |
2023-11-02 |
Univ California |
Método para generar células dendríticas humanas para inmunoterapia
|
JP6956071B2
(ja)
*
|
2015-08-31 |
2021-10-27 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換グアニジン基を含有するイミダゾ[4,5−c]環状化合物
|
EP3344622B1
(en)
|
2015-08-31 |
2021-07-07 |
3M Innovative Properties Company |
Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
|
WO2017046675A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
JP6883806B2
(ja)
*
|
2016-03-09 |
2021-06-09 |
国立大学法人大阪大学 |
化合物、及びこれを含む有機半導体材料
|
CA3023672A1
(en)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Pegylated liposomes and methods of use
|
US11344619B2
(en)
|
2016-05-16 |
2022-05-31 |
Access To Advanced Health Institute |
Formulation containing TLR agonist and methods of use
|
US10414779B2
(en)
|
2016-08-26 |
2019-09-17 |
3M Innovative Properties Company |
Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups
|
JP7240311B2
(ja)
|
2016-08-30 |
2023-03-15 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
薬物送達組成物およびその使用
|
CN110234401B
(zh)
|
2016-11-09 |
2024-03-01 |
德克萨斯大学系统董事会 |
用于适应性免疫调节的方法和组合物
|
EP3554344A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
CN116869457A
(zh)
|
2016-12-14 |
2023-10-13 |
比奥拉治疗股份有限公司 |
使用jak抑制剂治疗胃肠道疾病及装置
|
US10980739B2
(en)
|
2016-12-14 |
2021-04-20 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
BR112019011702A2
(pt)
|
2016-12-14 |
2019-10-22 |
Progenity Inc |
tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
|
CA3045472A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
WO2018112255A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
WO2018160552A1
(en)
|
2017-03-01 |
2018-09-07 |
3M Innovative Properties Company |
IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
|
CA3054156A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
US10618896B2
(en)
|
2017-08-22 |
2020-04-14 |
Dynavax Technologies Corporation |
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
|
EP3710059A1
(en)
|
2017-11-14 |
2020-09-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
EP3728255B1
(en)
|
2017-12-20 |
2022-01-26 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
CN111788202B
(zh)
|
2018-02-28 |
2024-03-01 |
3M创新有限公司 |
具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
|
TWI803637B
(zh)
|
2018-05-23 |
2023-06-01 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
JP7394790B2
(ja)
|
2018-05-24 |
2023-12-08 |
スリーエム イノベイティブ プロパティズ カンパニー |
N-1分枝状シクロアルキル置換イミダゾ[4,5-c]キノリン化合物、組成物、及び方法
|
CN113166143B
(zh)
|
2018-11-26 |
2024-06-04 |
舒万诺知识产权公司 |
N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
WO2020245706A1
(en)
|
2019-06-06 |
2020-12-10 |
3M Innovative Properties Company |
N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
EP3983408A1
(en)
|
2019-06-12 |
2022-04-20 |
3M Innovative Properties Company |
Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
IL293926A
(en)
|
2019-12-17 |
2022-08-01 |
Pfizer |
Antibodies unique to d47, pd-l1 and their uses
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
AU2021308586A1
(en)
|
2020-07-17 |
2023-03-02 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|